Ranbaxy

Ranbaxy Laboratories Limited is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines. Ranbaxy is ranked amongst the top ten global generic companies and has a presence in 23 of the top 25 pharma markets of the world. The company is headquartered in India. It has presence in 49 countries, with manufacturing facilities in 11 and a diverse product portfolio.

Ranbaxy was incorporated in 1961. Bhai Mohan Singh was the founder of the company. He bought the company from his cousins Ranjit Singh and Gurbax Singh. Ranbaxy's name is a fusion of Ranjit and Gurbax's names. Ranbaxy went public in 1973. Ranbaxy's first joint venture was set up in Lagos (Nigeria) in 1977. In 1985, Ranbaxy Research Foundation was established and Stancare, Ranbaxy's second pharmaceutical market division started functioning. In 1987, production started at Ranbaxy's Toansa Plant (Punjab) and with this Ranbaxy became India's largest manufacturer of antibiotics/antibacterials. In 1988, Ranbaxy's Toansa Plant got US FDA approval. In 1990, Ranbaxy was granted its first US patent, for Doxycyline. In 1993, Ranbaxy set up a joint venture in China. In 1994, Ranbaxy established regional headquarters in UK and USA. In the same year its GDR was listed in Luxembourgh Stock Exchange. In 1995, Ranbaxy acquired Ohm Laboratories, a manufacturing facility in the US and inaugurated state-of-the art new manufacturing wing at Ranbaxy's US subsidiary Ohm Laboratories Inc. In 1997, Ranbaxy crossed a sales turnover of Rs. 10,000 million.

In 1998, Ranbaxy entered USA, world's largest pharmaceutical market, with products under its own name. In the same year, Ranbaxy filed its first Investigational New Drug (IND) application with the Drugs Controller General OF India for approvals to conduct Phase 1 Clinical trials. In 1999, Ranbaxy commenced trials for its NCE. In 2000, Ranbaxy acquired Bayer's Generic business in Germany, and entered into Brazil, the largest pharmaceutical market in South America. In 2001, Ranbaxy set up a manufacturing facility in Vietnam. In 2003, Ranbaxy launched Cefuroxime Axetil after approval from USFDA. It was the first approval granted to any generic company for this product. In 2003, Ranbaxy and Glaxo SmithKline Plc entered into an alliance for drug discovery and development. In 2004, Ranbaxy acquired a wholly-owned subsidiary RPG (Aventis) SA and began operations in France as a Top 10 generic company. In 2005, Ranbaxy launched operations in Canada and acquired generic product portfolio from EFARMES of Spain. In 2006, Ranbaxy acquired Be Tabs pharmaceuticals of South Africa, unbranded generic business of GSK in Italy & Spain, and Terapia of Romania.

Major Achievements of Ranbaxy

Note: The above information was last updated on 21-07-2007